

Jeffrey deGraaf, CMT, CFA Rob Ginsberg

Small-Cap Strategy

While a confirmation of the improvement in trend, the recent surge in 20 and 65-day highs within the Russell 2000 has likely marked a near-team pause in its ascent, as recent readings have breached levels that have historically seen stocks post muted 1 and 3-month forward returns, before eventually resuming their underlying uptrend. We believe that investor patience is warranted, as this blow-off in momentum, coupled with the recent divergence of small-cap performance versus large-cap to be the beginning of this consolidation. With our trend work positive, we will be keeping a close eye on 20-day lows (6% yesterday), as readings north of 50% have historically provided a buyable oversold condition within uptrends. Near-term support resides at the 800 level, with 770 a more substantial level.

Our technical rankings favor those with a cyclical bend, with biotechnology, retail, leisure, banks, transportation and computer services software & systems topping our list of buy candidates during any market consolidations.

We have also included our initial take on some recent IPOs, providing a technical view on some of the new issues that have come to market over the past six months.

Rob Ginsberg


Important disclosure on last page

Sector Techni	ical Rankings	Industry Technical Rankings				
<u>Strongest</u>	<u>Weakest</u>	<u>Strongest</u>	<u>Weakest</u>			
Consumer Discretionary	Healthcare	Specialty Retail	Medical & Dental Instruments			
Producer Durables	Energy	Banks: Diversified	Communications Technology			
Materials & Processing	Technology	Computer Services Software & Systems	REITS			
		Biotechnology	Semiconductors & Components			

technical@renmac.com


Alex Meintel, CMT

MARKETS TEND TO DIFEST RECENT GAINS FOLLOWING ACCELERATION IN MET 65-DAY






CONSOLIDATION HELANG TO WORK OFF OURBOUGHT CONDITION






IN UPTRIND, SURGE IN 20-DAY LOWS PROVIDES BUYINGLE OUSSOLD CONDITION. FURTHER PURSUE 2000 PULLBACK LIKELY.












Discretionary, Durables Biggest Overweight Tech Biggest Underweight




Top Technically Ranked Russell 2000 Names

STMP	SPF	SYX	BBW	PHIK	RRR	AVD	ARIA	SPNC	QADA
DPZ	SIX	DW	ASCMA	MGRC	PRIM	AEPI	MDF	ZOLL	PROJ
GPI	TAST	RGR	SAH	WWD	TAL	SHLM	CBST	AMSWA	TRAK
CPWM	ABG	GCO	CBOU	HEES	WCAA	FUL	WCG	SPSC	CVLT
BEBE	SCSS	HIBB	MNRO	DXPE	ARII	CIA	HALO	FEIC	SABA
CONN	PIR	CRMT	SMP	FARO	AIT	DFG	CNC	ATMI	CNVO
BNHN	BODY	ACAT	MOV	GTLS	RA	MNTA	VPHM	ULTI	
LF	MGAM	PZZA	MW	MRLN	SSD	CRIS	MOH	INSP	
MTH	CHRS	VOXX	GWR	URI	ROCK	IDIX	MITI	MANH	
LAD	SGMS	NUS	AYR	CFX	MYE	MDVN	NRCI	CGNX	
ZUMZ	LGF	SHFL	ALK	ELRC	RTK	EXAS	PRSC	BLKB	
RYL	LZB	ASNA	ALGT	RUSHA	EXP	PGNX	ALOG	TYL	

New entrants highlighted in green




Sub-Sector Over/Under Weights



+ computer such software and systems largest industry o/w


COMMUNICATIONS, SEMI'S AND COMPONENTS








IPOs






<u>IPOs</u>





<u>IPOs</u>






IPOs






Optimal Exit in Producer Durables

Optimal exits are stocks that score poorly (5) in our work and are currently overbought within their downtrend. We would use recent strength to peel back or initiate short positions.





Optimal Exit in Pharma





Legal Disclaimer

Analyst Certification: The analyst(s) principally responsible for the preparation of this research report certify that the views expressed in this research report accurately reflect his/her (their) personal views about the subject security (ies) or issuer(s) and that his/her (their) compensation was not, is not, or will not be directly or indirectly related to the specific recommendations or views contained in this research report.

Analyst: The analyst does not serve as an officer, director, or advisory board member of the subject company.

The analyst or a member of the analyst's household does not have a long position in shares or derivatives of the subject company.

The analyst or a member of the analyst's household does not have a short position in shares or derivatives of the subject company.

Rafferty Capital Markets, LLC has not acted as an investment banker for the company(s) mentioned in this report in the past or will solicit in the future.

The person(s) responsible for preparing this report regularly trade the constituents of the CRB index, currencies, fixed income securities and stock indices.

Receipt of Compensation: The research analyst responsible for preparation of this report has not received any compensation from the subject company in the past 12 months.

Rafferty Capital Markets, LLC, Member SIPC, FINRA, (the "Firm") does not perform or seek to perform investment-banking services for these companies in the future. Analysts receive no direct compensation in connection with the firm's investment banking business. All Rafferty Capital Markets, LLC employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Rafferty Capital Markets, LLC and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by directors, analysts or employees and may effect transactions in and have long or short positions in the securities (options or warrants with respect thereto) mentioned herein. Analysts are not eligible for bonus compensation. Although the statements of fact in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included constitute the analyst's judgment as of the date of this report and are subject to change without notice. The firm may effect transactions as agent in the securities mentioned herein. This report is offered for information purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited.

Additional information available upon request.

Additional Significant Risk Factors and Investment Considerations: The securities or trading strategies discussed in this report may not be suitable for some investors. Investors must independently evaluate each issuer, security, or instrument discussed in this report and consult independent advisors where necessary.

- 1. Past Performance is not indicative of future results.
- 2. Market Risk: Securities may decline in value due to factors affecting securities markets generally or particular industries. The value of a security may be worth less than the original investment.
- 3. Concentration risk: Investing a substantial portion of assets in securities within a single industry or sector of the economy may be subject to greater price volatility or adversely affected by the performance of securities in that particular sector or industry.
- 4. Leverage Risk: Fluctuations in interest rates on borrowings or the dividend rates on preferred shares as a result of changes in short-term interest rates may reduce the return to common shareholders or result in fluctuations in the dividends paid on the common shares. There is no assurance that a leverage strategy will be successful.
- 5. Foreign Investment Risk: Investment in foreign securities (both governmental and corporate) may involve a high degree of risk. In regards to debt securities, such risks may impair the timely payment of principal and/or interest.
- 6. Short selling involves an inordinate amount of risk including the theoretical potential for unlimited losses and losses that can greatly exceed the principal amount invested. In contrast, the potential gain from short selling is generally limited to the principal amount invested. Short sellers can have their stock called away by the lender of the shares shorted, subjecting the short seller to incremental risk. Short sellers by definition must borrow shares, subjecting short sellers to margin risk. The risks cited here with respect to short selling are not all inclusive and investors should consult with their independent advisors prior to engaging in any recommended short selling strategies, including, if applicable, the short sale recommended in this report.

The risks detailed above are not inclusive. Other significant risk factors not identified here may be equally or more important to any particular investor in terms of assessing the overall risks associated with these securities. The information contained herein is illustrative and is not intended to predict actual results, which may differ substantially from those reflected herein. Investors should consider this report as only a single factor in making their investment decision.

Copyright © Renaissance Macro Research, LLC. 2011. All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Renaissance Macro Research, LLC. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of Renaissance Macro Research, LLC.

